About Solara Active Pharma Sciences Limited
Data last updated: 14 July 2026
Solara Active Pharma Sciences Limited is a public limited company based in Thane, Maharashtra, India. It specialises in api manufacturers, a part of the broader pharmaceuticals sector. Incorporated on 23 February 2017, the company has been in operation for over 9 years.
Registered with ROC Mumbai under CIN L24230MH2017PLC291636. Listed on BSE: 541540 and NSE: SOLARA.
Capital: an authorised share capital of ₹120 Cr and a paid-up capital of ₹47.98 Cr. Formerly known as Ssl Pharma Sciences Limited. It is led by directors including Ramakrishnan Rajagopal and Kausalya Santhanam.
Last AGM: 25 September 2025. Financial statements filed for year ended 31 March 2025. Office: Sector 30, Thane, Maharashtra.
As per NSE-filed consolidated financials for FY 2026, the company reported a revenue of ₹1,368.98 Cr, a growth of 6.64% compared to the previous year. The net worth stands at ₹1,255.55 Cr (up 14.46% YoY). Total assets are valued at ₹2,332.59 Cr (up 4.51% YoY).
The company has a workforce of approximately 1,656 employees as per the latest available data. Its group structure includes 2 subsidiaries.
The company is associated with 1 brand - Solara Active Pharma Sciences. As per MCA filings, the company has open charges of ₹507.5 Cr and satisfied charges of ₹2,480.69 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website solara.co.in.
-
EmailLocked
-
TelephoneLocked
-
Website
-
Social MediaLocked
-
Registered AddressCyber One Unit No. 902 Sector 30A, Plot No. 4 & 6 Vashi Navi Mumbai, Thane, Maharashtra, India – 400703
-
IndustryPharma, API Manufacturers
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Solara Active Pharma Sciences Limited
Solara Active Pharma Sciences Limited has one previous CIN (Corporate Identification Number): U24230MH2017PLC291636. The current CIN is L24230MH2017PLC291636, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24230MH2017PLC291636 | Current |
| U24230MH2017PLC291636 | Previous |
Associated Brands with Solara Active Pharma Sciences Limited
Solara Active Pharma Sciences Limited operates one associated brand: Solara Active Pharma Sciences. These brands represent Solara Active Pharma Sciences Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| APIs and intermediates are manufactured for therapeutic categories. | solara.co.in |
Business Activity of Solara Active Pharma Sciences Limited
Solara Active Pharma Sciences Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
Business activity turnover details for Solara Active Pharma Sciences Limited
Turnover contribution percentages and historical activity changes require an active report plan.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Auditor Details of Solara Active Pharma Sciences Limited
Solara Active Pharma Sciences Limited is audited by Delloitte Haskins & Sells LLP (ICAI peer reviewed, certificate valid till 2027-07-31) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| Delloitte Haskins & Sells LLP (ICAI peer reviewed, certificate valid till 2027-07-31) | FY 2026 | Declaration of unmodified opinion |
Board of Directors of Solara Active Pharma Sciences Limited
Solara Active Pharma Sciences Limited is currently managed by 8 directors, with 19 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Ramakrishnan Rajagopal | Director | 11 Apr 2018 | 8 Years 4 Months | Current |
|
Kausalya Santhanam
Also directs:
Strides Pharma Science Limited, Solara Active Pharma Sciences Limited, Synthix Global Pharma Solutions Limited and 2 more
|
Director | 11 Apr 2018 | 8 Years 4 Months | Current |
| Arun Kumar Pillai | Director | 04 Aug 2021 | 5 Years 0 Months | Current |
|
Sandeep Shashikantha Rao
Also directs:
Solara Active Pharma Sciences Limited
|
Managing Director | 21 Feb 2025 | 1 Years 5 Months | Current |
|
Manish Gupta
Also directs:
Solara Active Pharma Sciences Limited, Synthix Global Pharma Solutions Limited, Jagson Pal Pharmaceuticals Limited. and 1 more
|
Director | 22 Jul 2024 | 2 Years 0 Months | Current |
|
Rajendra Kumar Srivastava
Also directs:
Solara Active Pharma Sciences Limited, Latticed Advisors Llp, Happiest Minds Technologies Limited and 1 more
|
Director | 14 Nov 2023 | 2 Years 8 Months | Current |
Financials of Solara Active Pharma Sciences Limited FY 2026 filings available
Solara Active Pharma Sciences Limited reported revenue of ₹1,368.98 Cr (up 6.64% YoY) for FY 2026.
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹1,368.98 Cr | ₹1,283.76 Cr | ₹1,288.92 Cr | ₹1,443.81 Cr | ₹1,268.34 Cr | ₹1,616.88 Cr | ₹1,321.75 Cr |
| Other Income | ₹6.16 Cr | ₹8.32 Cr | ₹5.37 Cr | ₹22.55 Cr | ₹20.02 Cr | ₹28.77 Cr | ₹27.52 Cr |
| Total Income | ₹1,375.14 Cr | ₹1,292.08 Cr | ₹1,294.29 Cr | ₹1,466.36 Cr | ₹1,288.36 Cr | ₹1,645.65 Cr | ₹1,349.27 Cr |
| Cost of Materials Consumed | ₹672.77 Cr | ₹581.66 Cr | ₹760.65 Cr | ₹773.89 Cr | ₹858.86 Cr | ₹683.77 Cr | ₹602.15 Cr |
| Purchases of Stock-in-Trade | ₹3.49 Cr | ₹5.75 Cr | ₹5.1 Cr | ₹7.88 Cr | ₹53.78 Cr | ₹42.8 Cr | ₹29.67 Cr |
| Changes in Inventories | ₹8.25 Cr | ₹39 Cr | ₹39.27 Cr | ₹7.05 Cr | -₹258.75 Cr | -₹2.15 Cr | -₹32.95 Cr |
| Employee Benefit Expense | ₹219.2 Cr | ₹211.69 Cr | ₹243.92 Cr | ₹228.63 Cr | ₹236.34 Cr | ₹229.37 Cr | ₹204.13 Cr |
| Finance Costs | ₹94.75 Cr | ₹114.81 Cr | ₹105.11 Cr | ₹90.06 Cr | ₹75.28 Cr | ₹84.48 Cr | ₹77.89 Cr |
| Depreciation & Amortisation | ₹99.68 Cr | ₹99.25 Cr | ₹103.33 Cr | ₹111.19 Cr | ₹112.32 Cr | ₹108.66 Cr | ₹94.16 Cr |
| Other Expenses | ₹278.52 Cr | ₹239.38 Cr | ₹335.16 Cr | ₹292.47 Cr | ₹298.14 Cr | ₹277.22 Cr | ₹259.31 Cr |
| Total Expenses | ₹1,376.66 Cr | ₹1,291.54 Cr | ₹1,592.54 Cr | ₹1,511.17 Cr | ₹1,375.97 Cr | ₹1,424.15 Cr | ₹1,234.36 Cr |
| Profit Before Exceptional Items & Tax | -₹1.52 Cr | ₹54 Lakh | -₹298.25 Cr | -₹44.81 Cr | -₹87.61 Cr | ₹221.5 Cr | ₹114.91 Cr |
| Exceptional Items | -₹5.89 Cr | ₹0 | -₹190.17 Cr | ₹0 | -₹3.49 Cr | ₹0 | ₹0 |
| Profit Before Tax | -₹7.41 Cr | ₹54 Lakh | -₹488.42 Cr | -₹44.81 Cr | -₹91.1 Cr | ₹221.5 Cr | ₹114.91 Cr |
| Total Tax Expense | ₹0 | ₹0 | ₹78.54 Cr | -₹22.57 Cr | -₹32.81 Cr | ₹15 Lakh | ₹39 Lakh |
| Net Profit | -₹7.41 Cr | ₹54 Lakh | -₹566.96 Cr | -₹22.24 Cr | -₹58.29 Cr | ₹221.35 Cr | ₹114.52 Cr |
| attributable to Owners | -₹7.41 Cr | ₹54 Lakh | -₹567.39 Cr | -₹22.17 Cr | -₹58.15 Cr | ₹221.4 Cr | ₹110.9 Cr |
| attributable to NCI | ₹0 | -₹10,000 | ₹43 Lakh | -₹7 Lakh | -₹14 Lakh | -₹5 Lakh | -₹9 Lakh |
| Other Comprehensive Income | ₹2.85 Cr | ₹98 Lakh | ₹49 Lakh | -₹2.06 Cr | ₹1.89 Cr | -₹2.4 Cr | -₹3.71 Cr |
| Total Comprehensive Income | -₹4.56 Cr | ₹1.52 Cr | -₹566.47 Cr | -₹24.3 Cr | -₹56.4 Cr | ₹218.95 Cr | ₹110.81 Cr |
| EBITDA (computed) | ₹192.91 Cr | ₹214.6 Cr | -₹89.81 Cr | ₹156.44 Cr | ₹99.99 Cr | ₹414.64 Cr | ₹286.96 Cr |
| Basic EPS | ₹-1.68 | ₹0.14 | ₹-157.62 | ₹-6.16 | ₹-16.18 | ₹69.00 | ₹44.29 |
| Diluted EPS | ₹-1.68 | ₹0.14 | ₹-157.62 | ₹-6.16 | ₹-16.18 | ₹64.52 | ₹42.82 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹2,332.59 Cr | ₹2,231.84 Cr | ₹2,350.96 Cr | ₹2,899.06 Cr |
| Non-current Assets | ₹1,474.49 Cr | ₹1,503.11 Cr | ₹1,550.21 Cr | ₹1,711.74 Cr |
| Current Assets | ₹858.1 Cr | ₹728.73 Cr | ₹788.07 Cr | ₹1,187.32 Cr |
| Property, Plant & Equipment | ₹793.18 Cr | ₹738.68 Cr | ₹857.85 Cr | ₹920.58 Cr |
| Inventories | ₹317.87 Cr | ₹317.9 Cr | ₹359.7 Cr | ₹558.09 Cr |
| Trade Receivables | ₹438.72 Cr | ₹326.57 Cr | ₹348.52 Cr | ₹536.99 Cr |
| Cash & Equivalents | ₹4.48 Cr | ₹3.95 Cr | ₹8.44 Cr | ₹8.73 Cr |
| Equity (Net Worth) | ₹1,255.55 Cr | ₹1,096.91 Cr | ₹936.58 Cr | ₹1,502.46 Cr |
| Equity Share Capital | ₹44.51 Cr | ₹40.25 Cr | ₹36 Cr | ₹36 Cr |
| Borrowings (Non-current) | ₹110.45 Cr | ₹113.86 Cr | ₹105.83 Cr | ₹235.1 Cr |
| Borrowings (Current) | ₹554.09 Cr | ₹662.2 Cr | ₹894.06 Cr | ₹766.05 Cr |
| Total Debt (computed) | ₹664.54 Cr | ₹776.06 Cr | ₹999.89 Cr | ₹1,001.15 Cr |
| Current Liabilities | ₹893.91 Cr | ₹944.11 Cr | ₹1,242.79 Cr | ₹1,100.9 Cr |
| Total Liabilities | ₹1,077.04 Cr | ₹1,134.93 Cr | ₹1,414.38 Cr | ₹1,396.6 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₹152.91 Cr | ₹212.82 Cr | ₹108.87 Cr | ₹156.25 Cr | -₹242.09 Cr |
| Investing Cash Flow | -₹98.83 Cr | -₹36.83 Cr | -₹3.51 Cr | -₹81.14 Cr | -₹242.82 Cr |
| Financing Cash Flow | -₹53.55 Cr | -₹180.48 Cr | -₹105.65 Cr | -₹112.76 Cr | ₹333.6 Cr |
| Capital Expenditure | ₹52.82 Cr | ₹39.94 Cr | ₹41.06 Cr | ₹111.31 Cr | ₹208.59 Cr |
| Free Cash Flow (computed) | ₹100.09 Cr | ₹172.88 Cr | ₹67.81 Cr | ₹44.94 Cr | -₹450.68 Cr |
| Dividends Paid | ₹0 | ₹0 | ₹0 | ₹0 | ₹10.78 Cr |
| Net Change in Cash | ₹53 Lakh | -₹4.49 Cr | -₹29 Lakh | -₹37.65 Cr | -₹151.31 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹387.29 Cr | ₹349 Cr | ₹313.54 Cr | ₹319.15 Cr | ₹273.01 Cr | ₹300.31 Cr | ₹346.95 Cr | ₹363.49 Cr | ₹299.43 Cr | ₹248.73 Cr | ₹425.24 Cr | ₹352.31 Cr |
| Other Income | ₹4.69 Cr | ₹0 | ₹49 Lakh | ₹98 Lakh | ₹5.95 Cr | ₹1.49 Cr | ₹32 Lakh | ₹56 Lakh | ₹1.7 Cr | ₹45 Lakh | ₹1.18 Cr | ₹2.04 Cr |
| Total Income | ₹391.98 Cr | ₹349 Cr | ₹314.03 Cr | ₹320.13 Cr | ₹278.96 Cr | ₹301.8 Cr | ₹347.27 Cr | ₹364.05 Cr | ₹301.13 Cr | ₹249.18 Cr | ₹426.42 Cr | ₹354.35 Cr |
| Cost of Materials Consumed | ₹182.23 Cr | ₹175.71 Cr | ₹149.69 Cr | ₹165.14 Cr | ₹143.67 Cr | ₹143.96 Cr | ₹156.93 Cr | ₹137.1 Cr | ₹158.38 Cr | ₹157.76 Cr | ₹241.83 Cr | ₹202.68 Cr |
| Purchases of Stock-in-Trade | ₹77 Lakh | ₹2.72 Cr | ₹0 | ₹0 | ₹5.05 Cr | ₹0 | ₹70 Lakh | ₹0 | ₹15 Lakh | ₹25 Lakh | ₹3.12 Cr | ₹1.58 Cr |
| Changes in Inventories | ₹14.44 Cr | ₹8.17 Cr | ₹4.31 Cr | -₹18.67 Cr | -₹30.63 Cr | -₹9.1 Cr | ₹14.26 Cr | ₹64.47 Cr | ₹1.45 Cr | ₹57.51 Cr | -₹7.42 Cr | -₹12.27 Cr |
| Employee Benefit Expense | ₹55.47 Cr | ₹55.23 Cr | ₹54.86 Cr | ₹53.64 Cr | ₹52.29 Cr | ₹51.67 Cr | ₹52.71 Cr | ₹55.02 Cr | ₹56.01 Cr | ₹62.64 Cr | ₹64.12 Cr | ₹61.15 Cr |
| Finance Costs | ₹27.57 Cr | ₹22.45 Cr | ₹20.83 Cr | ₹23.9 Cr | ₹29.12 Cr | ₹26.54 Cr | ₹28.28 Cr | ₹30.87 Cr | ₹30.69 Cr | ₹25.37 Cr | ₹24.44 Cr | ₹24.61 Cr |
| Depreciation & Amortisation | ₹26.04 Cr | ₹25.57 Cr | ₹24.49 Cr | ₹23.58 Cr | ₹24.3 Cr | ₹24.54 Cr | ₹25.34 Cr | ₹25.07 Cr | ₹25.25 Cr | ₹25.96 Cr | ₹26.21 Cr | ₹25.91 Cr |
| Other Expenses | ₹76.72 Cr | ₹69.83 Cr | ₹69.95 Cr | ₹62.02 Cr | ₹57.26 Cr | ₹56.1 Cr | ₹61.04 Cr | ₹64.98 Cr | ₹73.68 Cr | ₹132.26 Cr | ₹85.96 Cr | ₹80.05 Cr |
| Total Expenses | ₹383.24 Cr | ₹359.68 Cr | ₹324.13 Cr | ₹309.61 Cr | ₹281.06 Cr | ₹293.71 Cr | ₹339.26 Cr | ₹377.51 Cr | ₹345.61 Cr | ₹461.75 Cr | ₹438.26 Cr | ₹383.71 Cr |
| Profit Before Exceptional Items & Tax | ₹8.74 Cr | -₹10.68 Cr | -₹10.1 Cr | ₹10.52 Cr | -₹2.1 Cr | ₹8.09 Cr | ₹8.01 Cr | -₹13.46 Cr | -₹44.48 Cr | -₹212.57 Cr | -₹11.84 Cr | -₹29.36 Cr |
| Exceptional Items | ₹86 Lakh | -₹6.75 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | -₹122.18 Cr | -₹62.77 Cr | -₹5.22 Cr | ₹0 |
| Profit Before Tax | ₹9.6 Cr | -₹17.43 Cr | -₹10.1 Cr | ₹10.52 Cr | -₹2.1 Cr | ₹8.09 Cr | ₹8.01 Cr | -₹13.46 Cr | -₹166.66 Cr | -₹275.34 Cr | -₹17.06 Cr | -₹29.36 Cr |
| Total Tax Expense | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹88.79 Cr | ₹0 | ₹0 | -₹10.25 Cr |
| Net Profit | ₹9.6 Cr | -₹17.43 Cr | -₹10.1 Cr | ₹10.52 Cr | -₹2.1 Cr | ₹8.09 Cr | ₹8.01 Cr | -₹13.46 Cr | -₹255.45 Cr | -₹275.34 Cr | -₹17.06 Cr | -₹19.11 Cr |
| attributable to Owners | ₹9.6 Cr | -₹17.43 Cr | -₹10.1 Cr | ₹10.52 Cr | -₹2.1 Cr | ₹8.09 Cr | - | -₹13.47 Cr | -₹255.34 Cr | -₹275.34 Cr | -₹17.16 Cr | -₹19.55 Cr |
| attributable to NCI | ₹0 | ₹0 | ₹0 | ₹0 | -₹10,000 | ₹0 | - | ₹0 | -₹11 Lakh | ₹0 | ₹10 Lakh | ₹44 Lakh |
| Other Comprehensive Income | ₹50 Lakh | ₹1.55 Cr | ₹81 Lakh | -₹1 Lakh | -₹62 Lakh | -₹7 Lakh | ₹1.68 Cr | -₹1 Lakh | ₹30 Lakh | -₹4 Lakh | ₹23 Lakh | ₹0 |
| Total Comprehensive Income | ₹10.1 Cr | -₹15.88 Cr | -₹9.29 Cr | ₹10.51 Cr | -₹2.72 Cr | ₹8.02 Cr | ₹9.69 Cr | -₹13.47 Cr | -₹255.15 Cr | -₹275.38 Cr | -₹16.83 Cr | -₹19.11 Cr |
| EBITDA (computed) | ₹62.35 Cr | ₹37.34 Cr | ₹35.22 Cr | ₹58 Cr | ₹51.32 Cr | ₹59.17 Cr | ₹61.63 Cr | ₹42.48 Cr | ₹11.46 Cr | -₹161.24 Cr | ₹38.81 Cr | ₹21.16 Cr |
| Basic EPS | ₹2.20 | ₹-3.98 | ₹-2.36 | ₹2.46 | ₹-0.93 | ₹2.03 | ₹2.54 | ₹-3.50 | ₹-70.93 | ₹-76.49 | ₹-4.77 | ₹-5.43 |
| Diluted EPS | ₹2.20 | ₹-3.98 | ₹-2.36 | ₹2.46 | ₹-0.93 | ₹2.03 | ₹2.54 | ₹-3.50 | ₹-70.93 | ₹-76.49 | ₹-4.77 | ₹-5.43 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹1,368.98 Cr | ₹1,283.76 Cr | ₹1,288.92 Cr | ₹1,443.81 Cr | ₹1,268.34 Cr | ₹1,616.88 Cr | ₹1,321.75 Cr |
| Other Income | ₹5.89 Cr | ₹9.14 Cr | ₹5.37 Cr | ₹22.14 Cr | ₹18.76 Cr | ₹28.41 Cr | ₹27.51 Cr |
| Total Income | ₹1,374.87 Cr | ₹1,292.9 Cr | ₹1,294.29 Cr | ₹1,465.95 Cr | ₹1,287.1 Cr | ₹1,645.29 Cr | ₹1,349.26 Cr |
| Cost of Materials Consumed | ₹672.77 Cr | ₹581.66 Cr | ₹760.66 Cr | ₹773.9 Cr | ₹858.86 Cr | ₹683.76 Cr | ₹602.15 Cr |
| Purchases of Stock-in-Trade | ₹3.49 Cr | ₹5.75 Cr | ₹5.1 Cr | ₹7.88 Cr | ₹53.78 Cr | ₹42.8 Cr | ₹29.67 Cr |
| Changes in Inventories | ₹8.25 Cr | ₹39 Cr | ₹39.27 Cr | ₹7.05 Cr | -₹258.75 Cr | -₹2.15 Cr | -₹32.95 Cr |
| Employee Benefit Expense | ₹219.2 Cr | ₹211.68 Cr | ₹243.92 Cr | ₹228.05 Cr | ₹234.2 Cr | ₹227.63 Cr | ₹202.24 Cr |
| Finance Costs | ₹94.24 Cr | ₹114.81 Cr | ₹105.97 Cr | ₹90.06 Cr | ₹75.27 Cr | ₹84.47 Cr | ₹77.88 Cr |
| Depreciation & Amortisation | ₹99.68 Cr | ₹99.25 Cr | ₹103.03 Cr | ₹110.9 Cr | ₹112.01 Cr | ₹108.31 Cr | ₹93.67 Cr |
| Other Expenses | ₹278.59 Cr | ₹241.83 Cr | ₹335.04 Cr | ₹292.89 Cr | ₹299.9 Cr | ₹279.51 Cr | ₹264.11 Cr |
| Total Expenses | ₹1,376.22 Cr | ₹1,293.98 Cr | ₹1,592.99 Cr | ₹1,510.73 Cr | ₹1,375.27 Cr | ₹1,424.33 Cr | ₹1,236.77 Cr |
| Profit Before Exceptional Items & Tax | -₹1.35 Cr | -₹1.08 Cr | -₹298.7 Cr | -₹44.78 Cr | -₹88.17 Cr | ₹220.96 Cr | ₹112.49 Cr |
| Exceptional Items | -₹5.89 Cr | ₹0 | -₹189.64 Cr | ₹0 | -₹3.49 Cr | ₹0 | ₹0 |
| Profit Before Tax | -₹7.24 Cr | -₹1.08 Cr | -₹488.34 Cr | -₹44.78 Cr | -₹91.66 Cr | ₹220.96 Cr | ₹112.49 Cr |
| Total Tax Expense | ₹0 | ₹0 | ₹78.54 Cr | -₹22.57 Cr | -₹33.1 Cr | ₹0 | ₹0 |
| Net Profit | -₹7.24 Cr | -₹1.08 Cr | -₹566.88 Cr | -₹22.21 Cr | -₹58.56 Cr | ₹220.96 Cr | ₹112.49 Cr |
| Other Comprehensive Income | ₹3.27 Cr | ₹1.06 Cr | ₹56 Lakh | -₹1.76 Cr | ₹2.01 Cr | -₹2.53 Cr | -₹3.29 Cr |
| Total Comprehensive Income | -₹3.97 Cr | -₹2 Lakh | -₹566.32 Cr | -₹23.97 Cr | -₹56.55 Cr | ₹218.43 Cr | ₹109.2 Cr |
| EBITDA (computed) | ₹192.57 Cr | ₹212.98 Cr | -₹89.7 Cr | ₹156.18 Cr | ₹99.11 Cr | ₹413.74 Cr | ₹284.04 Cr |
| Basic EPS | ₹-1.64 | ₹-0.27 | ₹-157.48 | ₹-6.17 | ₹-16.29 | ₹68.86 | ₹43.47 |
| Diluted EPS | ₹-1.64 | ₹-0.27 | ₹-157.48 | ₹-6.17 | ₹-16.29 | ₹64.40 | ₹42.03 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹2,276.59 Cr | ₹2,225.1 Cr | ₹2,346.6 Cr | ₹2,894.95 Cr |
| Non-current Assets | ₹1,467.9 Cr | ₹1,496.5 Cr | ₹1,555.95 Cr | ₹1,704.08 Cr |
| Current Assets | ₹808.69 Cr | ₹728.6 Cr | ₹790.65 Cr | ₹1,190.87 Cr |
| Property, Plant & Equipment | ₹786.58 Cr | ₹732.08 Cr | ₹851.24 Cr | ₹913.97 Cr |
| Inventories | ₹317.87 Cr | ₹317.9 Cr | ₹359.7 Cr | ₹558.09 Cr |
| Trade Receivables | ₹438.87 Cr | ₹326.57 Cr | ₹351.22 Cr | ₹539.65 Cr |
| Cash & Equivalents | ₹4 Cr | ₹3.81 Cr | ₹8.32 Cr | ₹8.55 Cr |
| Equity (Net Worth) | ₹1,255.44 Cr | ₹1,096.21 Cr | ₹937.42 Cr | ₹1,503.13 Cr |
| Equity Share Capital | ₹44.51 Cr | ₹40.25 Cr | ₹36 Cr | ₹36 Cr |
| Borrowings (Non-current) | ₹60.94 Cr | ₹113.86 Cr | ₹105.83 Cr | ₹235.1 Cr |
| Borrowings (Current) | ₹554.09 Cr | ₹662.2 Cr | ₹893.55 Cr | ₹766.05 Cr |
| Total Debt (computed) | ₹615.03 Cr | ₹776.06 Cr | ₹999.38 Cr | ₹1,001.15 Cr |
| Current Liabilities | ₹887.53 Cr | ₹938.07 Cr | ₹1,237.65 Cr | ₹1,096.12 Cr |
| Total Liabilities | ₹1,021.15 Cr | ₹1,128.89 Cr | ₹1,409.18 Cr | ₹1,391.82 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₹152.89 Cr | ₹212.8 Cr | ₹110.95 Cr | ₹156.17 Cr | -₹241.79 Cr |
| Investing Cash Flow | -₹50.14 Cr | -₹36.83 Cr | -₹4.66 Cr | -₹81.13 Cr | -₹243.07 Cr |
| Financing Cash Flow | -₹102.56 Cr | -₹180.48 Cr | -₹106.52 Cr | -₹112.76 Cr | ₹333.6 Cr |
| Capital Expenditure | ₹52.82 Cr | ₹39.94 Cr | ₹43.07 Cr | ₹111.31 Cr | ₹208.86 Cr |
| Free Cash Flow (computed) | ₹100.07 Cr | ₹172.86 Cr | ₹67.88 Cr | ₹44.86 Cr | -₹450.65 Cr |
| Dividends Paid | ₹0 | ₹0 | ₹0 | ₹0 | ₹10.78 Cr |
| Net Change in Cash | ₹19 Lakh | -₹4.51 Cr | -₹23 Lakh | -₹37.72 Cr | -₹151.26 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹387.29 Cr | ₹349 Cr | ₹313.54 Cr | ₹319.15 Cr | ₹273.01 Cr | ₹300.31 Cr | ₹346.95 Cr | ₹363.49 Cr | ₹299.43 Cr | ₹248.73 Cr | ₹425.24 Cr | ₹352.31 Cr |
| Other Income | ₹4.42 Cr | ₹0 | ₹49 Lakh | ₹98 Lakh | ₹5.95 Cr | ₹1.49 Cr | ₹32 Lakh | ₹1.38 Cr | ₹1.63 Cr | ₹44 Lakh | ₹1.23 Cr | ₹2.07 Cr |
| Total Income | ₹391.71 Cr | ₹349 Cr | ₹314.03 Cr | ₹320.13 Cr | ₹278.96 Cr | ₹301.8 Cr | ₹347.27 Cr | ₹364.87 Cr | ₹301.06 Cr | ₹249.17 Cr | ₹426.47 Cr | ₹354.38 Cr |
| Cost of Materials Consumed | ₹182.23 Cr | ₹175.71 Cr | ₹149.69 Cr | ₹165.14 Cr | ₹143.67 Cr | ₹143.96 Cr | ₹156.93 Cr | ₹137.1 Cr | ₹158.39 Cr | ₹157.76 Cr | ₹241.83 Cr | ₹202.68 Cr |
| Purchases of Stock-in-Trade | ₹77 Lakh | ₹2.72 Cr | ₹0 | ₹0 | ₹5.05 Cr | ₹0 | ₹70 Lakh | ₹0 | ₹15 Lakh | ₹25 Lakh | ₹3.12 Cr | ₹1.58 Cr |
| Changes in Inventories | ₹14.44 Cr | ₹8.17 Cr | ₹4.31 Cr | -₹18.67 Cr | -₹30.63 Cr | -₹9.1 Cr | ₹14.26 Cr | ₹64.47 Cr | ₹1.45 Cr | ₹57.51 Cr | -₹7.42 Cr | -₹12.27 Cr |
| Employee Benefit Expense | ₹55.47 Cr | ₹55.23 Cr | ₹54.86 Cr | ₹53.64 Cr | ₹52.28 Cr | ₹51.67 Cr | ₹52.71 Cr | ₹55.02 Cr | ₹56.01 Cr | ₹62.64 Cr | ₹64.12 Cr | ₹61.15 Cr |
| Finance Costs | ₹27.06 Cr | ₹22.45 Cr | ₹20.83 Cr | ₹23.9 Cr | ₹29.12 Cr | ₹26.54 Cr | ₹28.28 Cr | ₹30.87 Cr | ₹30.62 Cr | ₹25.37 Cr | ₹24.47 Cr | ₹25.51 Cr |
| Depreciation & Amortisation | ₹26.04 Cr | ₹25.57 Cr | ₹24.49 Cr | ₹23.58 Cr | ₹24.3 Cr | ₹24.54 Cr | ₹25.34 Cr | ₹25.07 Cr | ₹25.1 Cr | ₹25.96 Cr | ₹26.14 Cr | ₹25.83 Cr |
| Other Expenses | ₹76.83 Cr | ₹69.82 Cr | ₹69.93 Cr | ₹62.01 Cr | ₹60.05 Cr | ₹56.09 Cr | ₹61.03 Cr | ₹64.66 Cr | ₹73.64 Cr | ₹132.24 Cr | ₹85.92 Cr | ₹80.03 Cr |
| Total Expenses | ₹382.84 Cr | ₹359.67 Cr | ₹324.11 Cr | ₹309.6 Cr | ₹283.84 Cr | ₹293.7 Cr | ₹339.25 Cr | ₹377.19 Cr | ₹345.36 Cr | ₹461.73 Cr | ₹438.18 Cr | ₹384.51 Cr |
| Profit Before Exceptional Items & Tax | ₹8.87 Cr | -₹10.67 Cr | -₹10.08 Cr | ₹10.53 Cr | -₹4.88 Cr | ₹8.1 Cr | ₹8.02 Cr | -₹12.32 Cr | -₹44.3 Cr | -₹212.56 Cr | -₹11.71 Cr | -₹30.13 Cr |
| Exceptional Items | ₹86 Lakh | -₹6.75 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | -₹123.32 Cr | -₹62.77 Cr | -₹3.55 Cr | ₹0 |
| Profit Before Tax | ₹9.73 Cr | -₹17.42 Cr | -₹10.08 Cr | ₹10.53 Cr | -₹4.88 Cr | ₹8.1 Cr | ₹8.02 Cr | -₹12.32 Cr | -₹167.62 Cr | -₹275.33 Cr | -₹15.26 Cr | -₹30.13 Cr |
| Total Tax Expense | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹88.79 Cr | ₹0 | ₹0 | -₹10.25 Cr |
| Net Profit | ₹9.73 Cr | -₹17.42 Cr | -₹10.08 Cr | ₹10.53 Cr | -₹4.88 Cr | ₹8.1 Cr | ₹8.02 Cr | -₹12.32 Cr | -₹256.41 Cr | -₹275.33 Cr | -₹15.26 Cr | -₹19.88 Cr |
| Other Comprehensive Income | ₹71 Lakh | ₹1.6 Cr | ₹96 Lakh | ₹0 | -₹64 Lakh | ₹0 | ₹1.7 Cr | ₹0 | ₹32 Lakh | ₹0 | ₹24 Lakh | ₹0 |
| Total Comprehensive Income | ₹10.44 Cr | -₹15.82 Cr | -₹9.12 Cr | ₹10.53 Cr | -₹5.52 Cr | ₹8.1 Cr | ₹9.72 Cr | -₹12.32 Cr | -₹256.09 Cr | -₹275.33 Cr | -₹15.02 Cr | -₹19.88 Cr |
| EBITDA (computed) | ₹61.97 Cr | ₹37.35 Cr | ₹35.24 Cr | ₹58.01 Cr | ₹48.54 Cr | ₹59.18 Cr | ₹61.64 Cr | ₹43.62 Cr | ₹11.42 Cr | -₹161.23 Cr | ₹38.9 Cr | ₹21.21 Cr |
| Basic EPS | ₹2.23 | ₹-3.97 | ₹-2.36 | ₹2.46 | ₹-1.65 | ₹2.47 | ₹2.11 | ₹-3.20 | ₹-71.23 | ₹-76.49 | ₹-4.24 | ₹-5.52 |
| Diluted EPS | ₹2.23 | ₹-3.97 | ₹-2.36 | ₹2.46 | ₹-1.65 | ₹2.47 | ₹2.11 | ₹-3.20 | ₹-71.23 | ₹-76.49 | ₹-4.24 | ₹-5.52 |
Shareholding Pattern of Solara Active Pharma Sciences Limited
As per the shareholding pattern filed with NSE for the quarter ended May 2026, promoters hold 42.00%, foreign institutional investors hold 11.33%, domestic institutional investors hold 3.78%, retail and other public shareholders hold 42.89% of Solara Active Pharma Sciences Limited. The company had 70,037 shareholders on record.
| May 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Promoters | 42.00% | 42.00% | 42.00% | 42.01% | 42.01% | 37.94% |
| Public | 58.00% | 58.00% | 58.00% | 57.99% | 57.99% | 62.06% |
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | |
|---|---|---|---|---|---|---|---|---|
| Promoters | 42.00% | 37.94% | 30.49% | 40.97% | 39.71% | 44.11% | 41.88% | 40.55% |
| Public | 58.00% | 62.06% | 69.51% | 59.03% | 60.29% | 55.89% | 58.12% | 59.45% |
| Promoter change (YoY, %pts) | +4.06 | +7.45 | -10.48 | +1.26 | -4.40 | +2.23 | +1.33 | - |
Board & Governance of Solara Active Pharma Sciences Limited
As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Solara Active Pharma Sciences Limited has 8 directors - 4 independent and 2 executive. The board is chaired by Ramakrishnan Rajagopal.
| Director | Position | On board since | Listed boards |
|---|---|---|---|
| Ramakrishnan Rajagopal | Non-Executive - Independent Director · Chairperson | 2018-04-11 | 1 |
| Kausalya Santhanam | Non-Executive - Independent Director | 2018-04-11 | 2 |
| Arun Kumar Pillai | Non-Executive - Non Independent Director | 2021-08-04 | 3 |
| Sandeep Shashikantha Rao | Executive Director · CEO-MD | 2025-02-21 | 1 |
| Manish Gupta | Non-Executive - Non Independent Director | 2024-07-22 | 2 |
| Rajendra Kumar Srivastava | Non-Executive - Independent Director | 2023-11-14 | 2 |
| Rajiv Vijay Nabar | Non-Executive - Independent Director | 2023-11-14 | 2 |
| Mohanraj Sanjeevi | Executive Director | 2026-01-01 | 1 |
| Committee | Members |
|---|---|
| Audit Committee | Ramakrishnan Rajagopal (Chairperson), Kausalya Santhanam, Rajendra Kumar Srivastava, Rajiv Vijay Nabar |
| Nomination and remuneration committee | Rajendra Kumar Srivastava (Chairperson), Kausalya Santhanam, Rajiv Vijay Nabar, Ramakrishnan Rajagopal |
| Stakeholders Relationship Committee | Kausalya Santhanam (Chairperson), Sandeep Shashikantha Rao, Manish Gupta |
| Risk Management Committee | Rajiv Vijay Nabar (Chairperson), Kausalya Santhanam, Rajendra Kumar Srivastava, Ramakrishnan Rajagopal, Sandeep Shashikantha Rao |
| Corporate Social Responsibility Committee | Kausalya Santhanam (Chairperson), Ramakrishnan Rajagopal, Sandeep Shashikantha Rao |
Group Structure of Solara Active Pharma Sciences Limited
Solara Active Pharma Sciences Limited has 2 subsidiary companies. This group structure data is as of FY 2023. The corporate group structure reflects Solara Active Pharma Sciences Limited's business expansion strategy and organizational complexity.
| Company Name | CIN | Shares Held |
|---|---|---|
| Sequent Penems Private Limited | U24233KA2010PTC053548 | - |
| Chemsynth Laboratories Private Limited | U24297TG2009PTC064991 | - |
Showing major subsidiaries. Total: 2.
Charges & Borrowings of Solara Active Pharma Sciences Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 30 Jan 2025 | Others | ₹75 Cr | Open |
| 28 Sep 2022 | Yes Bank Limited | ₹75 Cr | Open |
| 28 Sep 2022 | Yes Bank Limited | ₹65 Cr | Open |
| 22 Nov 2021 | Others | ₹150 Cr | Open |
| 30 May 2019 | Others | ₹142.5 Cr | Open |
Total charge records: 26 View all charges
Employees and EPFO Compliance at Solara Active Pharma Sciences Limited
Solara Active Pharma Sciences Limited has a workforce of 1,656 employees as of Mar 25, 2024.
Employee and EPFO history for Solara Active Pharma Sciences Limited
Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
GST Compliance of Solara Active Pharma Sciences Limited
GST registrations and filing compliance for Solara Active Pharma Sciences Limited
State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
Credit Ratings, Litigation & Regulatory Alerts for Solara Active Pharma Sciences Limited
Credit ratings, litigation, and regulatory alerts for Solara Active Pharma Sciences Limited
Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Solara Active Pharma Sciences Limited
MSME payment history for Solara Active Pharma Sciences Limited
Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Solara Active Pharma Sciences Limited
Corporate group structure for Solara Active Pharma Sciences Limited
Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Solara Active Pharma Sciences Limited
MCA filings and documents for Solara Active Pharma Sciences Limited
Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Recent Activity on Solara Active Pharma Sciences Limited
Recent News on Solara Active Pharma Sciences Limited
Frequently Asked Questions about Solara Active Pharma Sciences Limited
Solara Active Pharma Sciences Limited is an active public limited company in the pharma sector based in Thane, Maharashtra, India. It was incorporated on 23 February 2017 (9+ years old) and is registered under CIN L24230MH2017PLC291636. Listed on BSE: 541540 and NSE: SOLARA. The company has 1,656 employees.
Solara Active Pharma Sciences Limited reported revenue of ₹1,368.98 Cr for FY 2026 (up 6.64% YoY) based on consolidated NSE filings.
The current directors of Solara Active Pharma Sciences Limited are:
- Ramakrishnan Rajagopal - Director
- Kausalya Santhanam - Director
- Arun Kumar Pillai - Director
- Sandeep Shashikantha Rao - Managing Director
- Manish Gupta - Director
- Rajendra Kumar Srivastava - Director
- Rajiv Vijay Nabar - Director
- Sanjeevi Mohanraj - Whole-Time Director
The primary industry of Solara Active Pharma Sciences Limited is pharma. The company specifically operates in api manufacturers. The company is currently active in this sector.
Yes. Solara Active Pharma Sciences Limited is listed on both BSE (code: 541540) and NSE (symbol: SOLARA).
Solara Active Pharma Sciences Limited can be reached at the registered office: Cyber One Unit No. 902 Sector 30A, Plot No. 4 & 6 Vashi Navi Mumbai, Thane, Maharashtra, India – 400703, or through the website solara.co.in.